A non-selective melanocortin analogue investigated for pigmentation and central effects, with no pharmaceutical approval
Overview
Melanotan 2 (MT-II) is a synthetic cyclic peptide that was developed as an analogue of α-MSH. In contrast to afamelanotide (Melanotan 1), it is a less selective melanocortin-system agonist, able to act on several receptors rather than on MC1R in the skin alone [1,2]. Early work in the 1990s demonstrated that it could increase pigmentation in humans [1]. Central effects on libido and erection were identified subsequently, prompting the development of other molecules within the same receptor family [2,3]. Melanotan 2 holds no FDA approval, whether for tanning or for any other therapeutic indication, and the FDA highlights significant safety concerns about compounded products containing it, including case reports of serious adverse events [4].
Biological Mechanism
The melanocortin system comprises several receptors belonging to the GPCR family. Activation of MC1R on melanocytes raises cAMP and eumelanin production, which can result in darkening of the skin. Melanotan 2 is not confined to MC1R; it can also activate melanocortin receptors within the central nervous system [2]. This wider activity accounts for why early experiments recorded not only pigmentation changes but also nausea, yawning, altered libido and erectile responses [2,3]. Put differently, the very non-selectivity that widens its biological activity also makes its side-effect profile more complex. MT-II should therefore not be regarded as a 'colour peptide' acting solely in the skin; it is a substance with systemic activity across multiple melanocortin pathways.
Research Evidence
An early study from 1996 evaluated MT-II in humans and reported increased pigmentation following a series of experimental exposures [1]. Further small studies investigated it in men with erectile dysfunction, observing an erectile response and increased libido in some participants [2,3]. While valuable as demonstrations of pharmacological activity, these studies provide no foundation for cosmetic or medical approval: they were small and relatively old, and they offer no long-term information on repeated use across a broad population. The later literature consists largely of observational studies, user reports and case reports of side effects. That is a weaker basis for judging benefit, but an important one for detecting safety signals.
Pigmentation vs. Central Effects
Melanotan 1 and Melanotan 2 differ in more than name. Afamelanotide was developed around MC1R activity and gained a specific medical approval for EPP, whereas MT-II activates several receptors and exhibits more pronounced central effects [2]. Consequently, pigmentation changes may occur alongside effects that have no direct connection to the skin. Nausea and yawning were frequent in early studies, and erection studies recorded sexual activity that did not necessarily depend on ordinary sexual stimulation [2,3]. This multi-system profile is why evaluating the safety of MT-II demands more than simply tracking skin colour.
Safety & Regulation
Melanotan II appears on the FDA's list of substances that may present significant safety risks in the context of compounding. The agency cites concerns over immunogenicity and peptide-related impurities, together with case reports of serious adverse events including priapism, sympathomimetic syndrome, posterior reversible encephalopathy syndrome and melanoma [4]. It should be stressed that a case report does not necessarily establish that the peptide caused the event. Published cases of melanoma following MT-II use, for instance, have sometimes involved additional risk factors such as intensive UV exposure [5], so a causal link to melanoma has not been demonstrated at the level of a controlled trial. Even so, the emergence of serious safety signals, coupled with the absence of large, long-term safety studies, leaves considerable uncertainty. Changes in moles or pigmented lesions may also make appropriate skin monitoring more difficult.
Case Reports, Causality & Material Quality
Case reports are well suited to identifying rare effects, but they cannot establish incidence or prove causality. A case of priapism after MT-II, for example, fits the central melanocortin mechanism described in the early studies and is therefore regarded as a plausible biological signal [6]. The question of melanoma risk is more complicated and calls for long-term epidemiological research. Beyond the mechanism itself, unapproved products raise questions about chemical identity, purity, sterility and degradation products. Where a substance is not manufactured as an approved pharmaceutical product, that uncertainty becomes an intrinsic part of its risk profile and cannot be separated from any evaluation of the peptide.
Summary
Melanotan 2 is a cyclic α-MSH analogue that acts on melanocortin receptors. Early studies investigated its effect on pigmentation without establishing any approved medical or cosmetic use [1-3], and the FDA reports significant concerns over the safety and quality of products containing MT-II, including case reports of serious adverse events [4-6]. It is an unapproved substance supplied for laboratory research use only.
Selected Research Sources
- Dorr R.T. et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 1996. PMID: 8637402
- Wessells H. et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research, 2000. PMID: 11035391
- Wessells H. et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. Journal of Urology, 1998. PMID: 9679884
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Entry for Melanotan II.
- Hjuler K.F. et al. Melanoma associated with the use of Melanotan-II. Dermatology, 2014. PMID: 24355990
- Dreyer B.A. et al. Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports, 2019. PMID: 30796078
